Physician profile
Norman Bettle
NPI 1033180039
$68,531.70
in general payments reported to CMS, 2019-2025
46 companies · $6,892 in 2025
The $6,892 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $13K · 2021: $15K · 2022: $7,264 · 2023: $4,978 · 2024: $8,490 · 2025: $6,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $6,425 · Travel and Lodging: $1,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,337.50 |
| Food and Beverage | $6,425.35 |
| Travel and Lodging | $1,596.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $33,618.31 | 2019-2022 | |
| Abbvie INC. | $26,289.84 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Acadia Pharmaceuticals INC | $683.34 | 2019-2025 | Nuplazid |
| Lundbeck LLC | $669.64 | 2022-2025 | Vyepti, Rexulti |
| Ucb, INC. | $654.31 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Emd Serono, INC. | $624.24 | 2019-2025 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $602.27 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Amgen INC. | $369.32 | 2019-2025 | Uplizna |
| Genzyme Corporation | $347.21 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $331.64 | 2019-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Mdd US Operations, LLC | $329.76 | 2019-2025 | Gocovri, Xadago, Myobloc |
| Tanabe Pharma America, INC. | $309.76 | 2019-2024 | |
| Argenx US, INC. | $309.56 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Novartis Pharmaceuticals Corporation | $305.80 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $254.56 | 2019-2022 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $243.70 | 2019-2025 | Ultomiris |
| Eisai INC. | $225.43 | 2019-2025 | |
| Lilly USA, LLC | $221.89 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Sk Life Science, INC. | $219.80 | 2020-2024 | |
| Pfizer INC. | $205.21 | 2023-2024 | |
| Genentech USA, INC. | $184.96 | 2019-2024 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Tg Therapeutics, INC. | $167.83 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $149.68 | 2023-2025 | Hyqvia, Gammagard |
| Biohaven Pharmaceutical Holding Company LTD. | $116.53 | 2022 | |
| Neurocrine Biosciences, INC. | $112.98 | 2019-2025 | Ingrezza, Ongentys |
| Otsuka America Pharmaceutical, INC. | $96.52 | 2023-2025 | Rexulti, Nuedexta |
| Kyowa Kirin, INC. | $89.38 | 2023-2024 | Nourianz |
| Acorda Therapeutics, INC | $86.79 | 2019-2023 | Inbrija |
| Biogen, INC. | $79.44 | 2019-2025 | Leqembi |
| Ultragenyx Pharmaceutical INC. | $75.21 | 2023-2024 | Dojolvi |
| Alnylam Pharmaceuticals INC. | $70.69 | 2021-2025 | Onpattro |
| Janssen Pharmaceuticals, INC | $68.95 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $64.13 | 2021-2023 | Dysport |
| Grifols USA, LLC | $43.53 | 2019-2023 | Gamunex-C |
| Supernus Pharmaceuticals, INC. | $43.46 | 2022-2025 | Qelbree |
| Mallinckrodt Enterprises LLC | $33.70 | 2019 | |
| Axsome Therapeutics, INC. | $33.13 | 2025 | Symbravo |
| Biohaven Pharmaceuticals, INC. | $32.59 | 2021 | |
| Averitas Pharma INC. | $25.63 | 2023 | Qutenza |
| Assertio Therapeutics, INC. | $24.72 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $24.06 | 2024 | Wainua |
| Livanova USA, INC. | $20.01 | 2019 | |
| Abbott Laboratories | $19.96 | 2021 | |
| Ani Pharmaceuticals, INC. | $17.85 | 2025 | Purified Cortrophin Gel |
| Impel Pharmaceuticals INC. | $17.67 | 2023 | Trudhesa |
| Upsher-Smith Laboratories LLC | $16.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Bettle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.